Lesogaberan

Lesogaberan (AZD-3355) was[1] an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD).[2] As a GABA_B receptor agonist,[3] it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.[4]

Lesogaberan

Names
IUPAC name ((R)-3-Amino-2-fluoropropyl)phosphinic acid
Other names AZD-3355
Identifiers
CAS Number	344413-67-8=
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL448343
ChemSpider	23254384
ECHA InfoCard	100.133.162
IUPHAR/BPS	7705
PubChem CID	9833984
UNII	4D6Q6HGC7Z
CompTox Dashboard (EPA)	DTXSID20188011
InChI InChI=1S/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1 Key: LJNUIEQATDYXJH-GSVOUGTGSA-N InChI=1/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1 Key: LJNUIEQATDYXJH-GSVOUGTGBQ
SMILES O=[PH](O)C[C@H](F)CN
Properties
Chemical formula	C3H9FNO2P
Molar mass	141.082 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is  ?)
Infobox references

References

1. AstraZeneca. "AZD3355". Retrieved 30 December 2011.
2. Bredenoord, Albert J. (2009). "Lesogaberan, a GABA_B agonist for the potential treatment of gastroesophageal reflux disease". IDrugs. 12 (9): 576–584. PMID 19697277.
3. Alstermark; Amin, K; Dinn, SR; et al. (2008). "Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors". Journal of Medicinal Chemistry. 51 (14): 4315–4320. doi:10.1021/jm701425k. PMID 18578471.
4. Brian E. Lacy; Robert Chehade; Michael D. Crowell (2010). "Lesogaberan". Drugs of the Future. 35 (12): 987–992. doi:10.1358/dof.2010.035.012.1540661.